文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

多奈单抗治疗早期症状性阿尔茨海默病:TRAILBLAZER-ALZ 2随机临床试验

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

这项多中心、随机、双盲、安慰剂对照的18个月3期试验纳入1736例早期症状性阿尔茨海默病伴淀粉样蛋白和tau病理的受试者,评估多奈单抗的疗效与不良事件。多奈单抗组在76周时iADRS和CDR-SB评分变化均显著优于安慰剂组,但淀粉样蛋白相关影像学异常水肿/积液和输注相关反应发生率更高。

要点

  • 多奈单抗显著减缓低/中tau人群和联合人群76周时的临床进展。
  • 低/中tau人群iADRS评分变化多奈单抗组-6.02 vs 安慰剂组-9.27,差值3.25。
  • 淀粉样蛋白相关影像学异常水肿/积液发生率多奈单抗组24.0% vs 安慰剂组2.1%。

核心结论

  • 在伴有淀粉样蛋白和tau病理的早期症状性阿尔茨海默病患者中,多奈单抗在低/中tau人群及低/中和高tau联合人群中于76周时显著减缓临床进展。

研究设计与样本

  • 多中心(8个国家277个医学研究中心/医院)、随机、双盲、安慰剂对照的18个月3期试验。
  • 纳入1736例早期症状性阿尔茨海默病(轻度认知障碍/轻度痴呆)伴淀粉样蛋白及低/中或高tau病理的受试者,随机1:1接受多奈单抗(n=860)或安慰剂(n=876)静脉给药每4周一次共72周。

主要发现

  • 76周时iADRS评分最小二乘均值变化:低/中tau人群多奈单抗组-6.02(95%CI -7.01至-5.03)vs 安慰剂组-9.27(95%CI -10.23至-8.31),差值3.25(95%CI 1.88-4.62),P<.001。
  • 76周时iADRS评分最小二乘均值变化:联合人群多奈单抗组-10.2(95%CI -11.22至-9.16)vs 安慰剂组-13.1(95%CI -14.10至-12.13),差值2.92(95%CI 1.51-4.33),P<.001。
  • 76周时CDR-SB评分最小二乘均值变化:低/中tau人群多奈单抗组1.20(95%CI 1.00-1.41)vs 安慰剂组1.88(95%CI 1.68-2.08),差值-0.67(95%CI -0.95至-0.40),P<.001。
  • 76周时CDR-SB评分最小二乘均值变化:联合人群多奈单抗组1.72(95%CI 1.53-1.91)vs 安慰剂组2.42(95%CI 2.24-2.60),差值-0.7(95%CI -0.95至-0.45),P<.001。
  • 淀粉样蛋白相关影像学异常水肿/积液:多奈单抗组205例(24.0%,其中52例有症状)vs 安慰剂组18例(2.1%,研究期间0例有症状);输注相关反应:多奈单抗组74例(8.7%)vs 安慰剂组4例(0.5%);多奈单抗组3例死亡、安慰剂组1例死亡被认为与治疗相关。

关键数值与推荐

  • 24项门控结局中23项达统计学显著。
  • 统计学检验分配α=.04用于低/中tau人群结局检验,其余α=.01用于联合人群结局检验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are limited efficacious treatments for Alzheimer disease. OBJECTIVE: To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyloid plaque. DESIGN, SETTING, AND PARTICIPANTS: Multicenter (277 medical research centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology based on positron emission tomography imaging from June 2020 to November 2021 (last patient visit for primary outcome in April 2023). INTERVENTIONS: Participants were randomized in a 1:1 ratio to receive donanemab (n = 860) or placebo (n = 876) intravenously every 4 weeks for 72 weeks. Participants in the donanemab group were switched to receive placebo in a blinded manner if dose completion criteria were met. MAIN OUTCOMES AND MEASURES: The primary outcome was change in integrated Alzheimer Disease Rating Scale (iADRS) score from baseline to 76 weeks (range, 0-144; lower scores indicate greater impairment). There were 24 gated outcomes (primary, secondary, and exploratory), including the secondary outcome of change in the sum of boxes of the Clinical Dementia Rating Scale (CDR-SB) score (range, 0-18; higher scores indicate greater impairment). Statistical testing allocated α of .04 to testing low/medium tau population outcomes, with the remainder (.01) for combined population outcomes. RESULTS: Among 1736 randomized participants (mean age, 73.0 years; 996 [57.4%] women; 1182 [68.1%] with low/medium tau pathology and 552 [31.8%] with high tau pathology), 1320 (76%) completed the trial. Of the 24 gated outcomes, 23 were statistically significant. The least-squares mean (LSM) change in iADRS score at 76 weeks was -6.02 (95% CI, -7.01 to -5.03) in the donanemab group and -9.27 (95% CI, -10.23 to -8.31) in the placebo group (difference, 3.25 [95% CI, 1.88-4.62]; P < .001) in the low/medium tau population and -10.2 (95% CI, -11.22 to -9.16) with donanemab and -13.1 (95% CI, -14.10 to -12.13) with placebo (difference, 2.92 [95% CI, 1.51-4.33]; P < .001) in the combined population. LSM change in CDR-SB score at 76 weeks was 1.20 (95% CI, 1.00-1.41) with donanemab and 1.88 (95% CI, 1.68-2.08) with placebo (difference, -0.67 [95% CI, -0.95 to -0.40]; P < .001) in the low/medium tau population and 1.72 (95% CI, 1.53-1.91) with donanemab and 2.42 (95% CI, 2.24-2.60) with placebo (difference, -0.7 [95% CI, -0.95 to -0.45]; P < .001) in the combined population. Amyloid-related imaging abnormalities of edema or effusion occurred in 205 participants (24.0%; 52 symptomatic) in the donanemab group and 18 (2.1%; 0 symptomatic during study) in the placebo group and infusion-related reactions occurred in 74 participants (8.7%) with donanemab and 4 (0.5%) with placebo. Three deaths in the donanemab group and 1 in the placebo group were considered treatment related. CONCLUSIONS AND RELEVANCE: Among participants with early symptomatic Alzheimer disease and amyloid and tau pathology, donanemab significantly slowed clinical progression at 76 weeks in those with low/medium tau and in the combined low/medium and high tau pathology population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04437511.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023. PMID: 37459141. doi:10.1001/jama.2023.13239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。